Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Status:
Open
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
NCT#03609216
